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B
reast cancer has long been at the top of both incidence and cause of cancer death in women worldwide. 1 Recent studies have shown that, in the US, the incidence of breast cancer death has been overtaken by lung cancer. 2 This is due largely to the effectiveness of Trastuzumab in the treatment of human epidermal growth factor receptor 2 (HER2) amplifi ed breast cancer, either at the early or advanced stage of disease. 3, 4 Therefore, HER2 testing is an important part of the pathological examination, and should be performed in all breast cancer patients. 5, 6 Immunohistochemistry (IHC) and fl uorescence in situ hybridization (FISH) methods have been the mainstay for determining HER2 status. 5 More recently, the dual in situ hybridization assay (DISH) method has been introduced as an alternative approach to FISH in the assessment of HER2 gene copy number. Head-to-head comparisons between FISH and DISH have been performed, and both methods showed good correlation and agreement. 7, 8 Since the DISH test relies on visual inspection of individuals, inter-observer variation may be an issue. Here, the inter-observer reproducibility in the assessment of HER2 DISH test was evaluated.
Materials and Methods
Sixty-nine invasive ductal carcinoma specimens that had been submitted to the Department of Pathology, King Chulalongkorn Memorial Hospital for HER2 DISH assay during 2012-2013 were included in the study. Fifty-eight cases were institutional cases while the remaining eleven cases were specimens received from other institutes. The morphological grading was available for 55 institutional cases (6 grade 1, 29 grade 2, and 20 grade 3). The HER2 IHC score using the ASCO/CAP guidelines 5 was available for all 58 institutional cases (32 cases with 2+, 26 cases with 3+).
The 4 micron-thick sections were prepared from formalin-fi xed paraffi n-embedded tissue of invasive carcinoma specimens. Sections were then stained with Ventana Benchmark XT system (Roche Diagnostics), using an Inform HER2 Dual ISH DNA Probe Cocktail (Ventana Medical System). The HER2 signals were visualized with an UltraView SISH DNP Detection Kit (Ventana Medical Systems) while the chromosome 17 centromere (CEP17) signals were visualized with an UltraView Red ISH DIG Detection kit (Ventana Medical Systems).
One pathologist (SS) inspected the DISH slides and digitally captured 10-20 images of the invasive components at the x600 magnifi cation, using Olympus DP22 digital camera for microscopes (Olympus Optical CO. LTD., Japan). Two investigators (TA and TC), without the knowledge of HER2 IHC status, independently counted the signals of 20 tumor cells with well-visualized signals, and calculated the HER2/CEP17 ratio and HER2/nucleus ratio. Interpretation of the HER2 gene copy number was made according to the ASCO/CAP guidelines as shown in Table 1 . 5 The results were then compared between the two investigators. 
Statistical analysis
We constructed a scatter diagram from the HER2/CEP17 ratios of both investigators and made a comparison. The Spearman's correlation coeffi cient (Rho) was calculated using SPSS statistic 20 (IBM Corporation, New York, USA). The Rho of 0 to 1 indicates a positive correlation and -1 to 0 indicates negative correlation. The strength of correlation coeffi cients is as follows: 0 and 1 indicate zero and perfect correlation respectively; ±0.1 to ±0.3 indicate weak correlation; ±0.4 to ±0.6 indicate moderate correlation; and ±0.7 to ±0.9 indicate strong correlation. A p-value was calculated using p-value of < 0.05 as the cut off point for statistical signifi cance.
The agreement of both investigators (amplifi ed vs.
non-amplifi ed) was compared using ĸ statistic. The ĸ statistic of 0 to 0.4 indicates poor agreement, 0.4 to 0.6 indicates moderate agreement, 0.6 to 0.8 indicates good agreement and 0.8 to 1 indicates excellent agreement.
Results
Two cases were considered uncountable. One example showed only CEP17 signals without HER2 signals and was regarded as uncountable by both investigators.
Another case showed strong CEP17 signals with faint and small HER2 signals in only a small portion of the tumor cells. This case was regarded as uncountable by investigator 1 but countable by the other (HER2/CEP17 = 0.76, non-amplifi ed). These two cases were excluded from analysis. There were 5 disagreed cases as shown in Table 2 . All of them are considered non-amplifi ed by investigator 1 and amplifi ed by investigator 2. Table 3 shows the correlation between the IHC score and DISH HER2 status, excluding the 5 discordant cases and 2 failed DISH cases. The tumors with IHC score 2+ were 14% HER2 amplifi ed by DISH method while the tumors with IHC score 3+ were 77% HER2 amplifi ed by DISH method. Agreement of both investigators for HER2 gene diagnosis was 92.75 % (ĸ = 0.848), refl ecting an excellent agreement. The HER2/CEP17 ratio of investigator 1 and 2 ranged from 0.8 to 13.46 and 0.76 to 11.63 respectively. 26 cases were interpreted as HER2-amplifi ed by investigator 1, while investigator 2 interpreted 31 cases as amplifi ed. None of the cases was in the equivocal category or showed heterogeneous HER2 gene copy number. Representative images of HER2-amplifi ed and nonamplifi ed are depicted in Figure 1 and 2, respectively. The HER2/CEP17 ratios obtained from both investigators were compared. The scatter diagrams revealed a strong correlation between the two (Rho = 0.883, p < 0.001) (Figure 3) . The case by case comparison is shown in (Figure 4 ). All 5 discordant cases have HER2/CEP17 ratios of less than 3 and most of them fall in the equivocal range of the previous ASCO guideline. 9 The HER2 count and CEP17 count were compared separately. Both HER2 and CEP17 counts from two investigators show strong correlation (HER2 count: Rho = 0.955, p < 0.001; CEP17 count: Rho = 0.779, p < 0.001). The scatter diagrams are shown in Figure 5 and 6. 
Reproducibility in the Assessment of HER2 DISH in Breast Cancer

Discussion
Discovery of HER2 and its implication in breast cancer is one of the examples of molecular oncology in which fundamental biological knowledge has been transformed into a practical application and has saved lives. To be able to fully appreciate the importance of this knowledge, HER2 status must be established in virtually all breast cancer cases. Accessibility to the HER2 tests is dependent on overcoming technical diffi culty, logistical issues, interpretation diffi culty, and cost. HER2 immunohistochemistry (IHC) has been used widely at an acceptable cost and has proven to be a great screening tool for determining HER2 status. 10 When HER2 IHC status is inconclusive (2+), assessment of HER2 gene copy number is mandatory and the FISH method has been regarded as the gold standard for this purpose for many years. FISH technique, however, requires the costly fl uorescent microscope for visualization. HER2 DISH assay that can assess the gene copy number under an ordinary microscope has emerged as an alternative tool to FISH. Multiple studies validating the HER2 DISH assay with FISH have shown promising results. 7, 8 Comparison between DISH and FISH methods is shown in Table 4 . We can expect the shift from the FISH assay to DISH in the near future.
Determination of the HER2 gene copy number is typically done by manual counting 5 , and interpersonal and even intrapersonal reproducibility may have an impact on the testing result. To address this issue, two observers were asked to independently assess the captured DISH images in this study. Very high correlation was found in the result obtained from the two investigators, and this implies that all tumor samples enrolled were reasonably homogenous in terms of HER2 status. Previous evaluations of intratumoral heterogeneity in breast cancer have also demonstrated similar results. 11, 12 Having said that, we do acknowledge the increasingly recognized cases of breast cancers with heterogeneous HER2 copy number 13, 14 but such an example was not found in our relatively small series of cases. The ASCO 2013 set the cut-off for HER2/CEP17 ratio at 2.0 for a tumor to be assigned as being 'HER2 amplifi ed'. As expected, cases with discrepancy in the results in our cohort had a HER2/CEP17 ratio around that level (negative for or low level of amplifi cation). Multiple studies have shown that the response to Trastuzumab therapy correlates highly with the level of amplifi cation, with a signifi cant response noted when HER2/CEP17 > 6. 6, 15 Therefore, the discrepancy cases in our series are unlikely to have a huge impact on the patients' long term survival.
Conclusion
The DISH method for determining the HER2 gene copy number is highly reliable, with high inter-observer reproducibility. Only a few discrepancy cases fell into the range of negative or low level of HER2 gene amplifi cation. The high inter-observer reproducibility also indicates that, in terms of HER2 status, most of the invasive breast carcinomas are fairly homogeneous throughout the lesion.
